Pelosi ’s radical plan leaves lung cancer patients behind

Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new lung cancer diagnoses and 140,000 deaths from the disease. Although diagnostic capabilities to detect lung cancer have crossed anew frontier, with identification down to the genetic level, continued biopharmaceutical research is needed to increase survival rates and ensure patients are diagnosed as early as possible.

Source: The Catalyst - October 23, 2019 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Research and Development Economic Impact Research and Investment Pelosi Plan Source Type: news